AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01573117 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RhinoChill
Description: Nasopharyngeal cooling with the RhinoChill device
Study NCT00824720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Device
Description: inserted for 14 days
Study NCT00824720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Device
Description: inserted for 14 days
Study NCT00824720 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Device
Description: inserted for 14 days
Study NCT00078793 — intervention group
Intervention type: DRUG
Intervention: Enbrel®
Description: Etanercept alone, etanercept plus methotrexate or other DMARDs
Study NCT01769807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP adaptation was performed by a sleep technician and the patients were instructed to use this for 1 month.
Study NCT03481075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomechanical computer program
Description: Fusion assisting software for image-guided intervention
Study NCT03942666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: tablet of CHF 6532
Study NCT03942666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: tablet of CHF 6532
Study NCT03942666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: tablet of CHF 6532
Study NCT03942666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: tablet of CHF 6532
Study NCT03942666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment E
Description: Placebo tablet of CHF 6532
Study NCT03942666 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Treatment F
Description: tablet of CHF 6532
Study NCT04131426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remune
Description: Remune is intended for the dietary management of disease related malnutrition especially in patients with precachexia or cachexia due to cancer or COPD
Study NCT04131426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXCAP©®
Description: EXCAP©® is a home-based low-to-moderate intensity program that employs a tailored walking prescription and total body resistance exercises
Study NCT01750983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Dose Escalation Group Starting Dose: 1.5 mg by vein over 90 minutes on Day 1 of each 28 day cycle.~Dose Expansion Group Starting Dose for Ipilimumab: Maximum tolerated dose (MTD) from Dose Escalation Group.
Study NCT01750983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dose Escalation Group Starting Dose: 10 mg by mouth on Days 1-21 of each 28 day cycle.~Dose Expansion Group Starting Dose for Lenalidomide: Maximum tolerated dose (MTD) from Dose Escalation Group.
Study NCT03233607 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Description: On postpartum day 1 and day 2, a sample of blood will be drawn in the morning for hemoglobin and hematocrit estimation.
Study NCT01610661 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet
Description: Unrefined-carbohydrate refers to foods made with 100% whole grains (wheat, rice, corn). Refined-carbohydrate refers to foods made with white flour (e.g., bread, pasta) or white rice. Simple-carbohydrate refers to foods made with sucrose (50% glucose/50% fructose) and high-fructose corn syrup.
Study NCT00094705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN2/4delta30(ME) Vaccine
Description: Live attenuated rDEN2/4delta30(ME) vaccine (one of two doses)
Study NCT03726671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% Cho diet
Description: Subjects will consume meals containing 100% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
Study NCT00683241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVac-L
Description: Subjects will receive three doses of intradermal vaccination with \~5-10 x 106 dendritic cells (DCVax-L) on days 0, 14 and 28
Study NCT02829177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Study NCT02829177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00094705 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for rDEN2/4delta30(ME) vaccine
Study NCT02339935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Analogue Functional Analysis
Description: The Brief AFA seeks to identify the function of the challenging behavior by creating controlled test conditions in which specific responses are provided for challenging behavior (e.g., attention, escape from task demands, access to tangible - including variants of each as needed), as well as a control condition in which continual access to attention and preferred items is provided. It consists of a 30-90-minute abbreviated analysis comprised of a single exposure to 2-5-minute test and control conditions, along with replication of applicable test conditions and a treatment probe, which provides evidence of challenging behavior function faster than other methods.
Study NCT01251172 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo in vitro treated autologous peripheral blood stem cell transplant
Study NCT01251172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given orally
Study NCT01251172 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Mobilization
Description: Undergo standard mobilization
Study NCT01251172 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In Vitro-Treated Peripheral Blood Stem Cell Transplantation
Description: Undergo in vitro treated autologous peripheral blood stem cell transplant
Study NCT01251172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01251172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT01438567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone/naloxone prolonged release (OXN PR) tablets
Description: Drug: Oxycodone/naloxone prolonged release tablets Arms: OXN PR Dosage: 2x50/25mg daily or 2x60/30mg daily or 2x70/35mg daily or 2x80/40mg daily
Study NCT01438567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone prolonged release (OxyPR) tablets
Description: Drug: Oxycodone prolonged release tablets Arms: OxyPR Dosage: 2x50mg daily or 2x60mg daily or 2x70mg daily or 2x80mg daily
Study NCT04640324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nutraceutical therapy
Description: Oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day for six months
Study NCT04640324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nutraceutical therapy
Description: Oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day for six months
Study NCT01573117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cold crystalloid infusions, 0.9%NaCl or Ringer's solution
Description: Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
Study NCT02434861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant
Study NCT02434861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: P-gp substrate
Study NCT02434861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: BCRP substrate
Study NCT02434861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cooperstown Cocktail
Description: Midazolam, omeprazole, warfarin, caffeine, and dextromethorphan
Study NCT03890510 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate solution
Description: Patients in both groups will receive Ringer's lactate solution continuously during operation with different infusion volume.
Study NCT03890510 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spine surgery under general Anesthesia in the prone position
Description: The surgery, general anesthesia, and the placement of the prone position will be performed according to the standard procedures.
Study NCT01498861 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ortho-Cyclen
Description: Ortho-cyclen is an oral contraceptive.
Study NCT01498861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ortho-Cyclen
Description: Ortho-cyclen is an oral contraceptive.
Study NCT01498861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Dolutegravir is an experimental HIV drug
Study NCT01498861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a tablet with no drug in it
Study NCT04170374 — intervention group
Intervention type: OTHER
Intervention: Routine medical record data collection
Description: The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
Study NCT04170374 — intervention group
Intervention type: OTHER
Intervention: Interviews with service providers
Description: Clinicians and lay staff will be interviewed regarding the ART initiation process.
Study NCT02486588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: See detailed study description for overview of the different financial incentive-based interventions in this study
Study NCT03906968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SinuSonic Device
Description: A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion
Study NCT01109004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive a second autologous PBSC transplant with the same conditioning regimen as the first transplant. All patients will also receive maintenance lenalidomide which will start after the second transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
Study NCT01109004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lenalidomide, bortezomib and dexamethasone
Description: All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive consolidation therapy with RVD (lenalidomide 15 mg/day on Days 1-14, dexamethasone 40mg on Days 1, 8 and 15, and bortezomib 1.3mg/m2 on Days 1, 4, 8 and 11 of every 21 day cycle, patients will receive four cycles). All patients will also receive maintenance lenalidomide which will start after consolidation therapy. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
Study NCT01109004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive maintenance with lenalidomide (15 mg daily). Maintenance lenalidomide will start after the first autologous transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
Study NCT00862680 — intervention group
Intervention type: PROCEDURE
Intervention: 4-Dimensional Computed Tomography
Description: Undergo 4D PET/CT
Study NCT00862680 — intervention group
Intervention type: PROCEDURE
Intervention: 4D PET Scan
Description: Undergo 4D PET/CT scan
Study NCT02339935 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Brief AFA
Description: These participants will receive typical standard of care procedures while hospitalized, but will not receive the additional behavioral intervention
Study NCT01480752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lornoxicam
Description: PDL injection of 0/2 ml of lornoxicam (4mg/ml),before the root therapy and after the inferior alveolar injection
Study NCT01159249 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vildagliptin
Study NCT03505567 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: KOWA OCT Bi-µ
Description: Non-contact, ultra-high resolution ophthalmic imaging system for fundus imaging and axial cross-sectional and three-dimensional imaging of retinal structures.
Study NCT03505567 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Optovue iVue 100
Description: U.S. Food and Drug Administration (FDA) cleared and commercially available Optovue iVue 100
Study NCT02343536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azacitidine
Study NCT02343536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT02343536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Study NCT02343536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT02343536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Study NCT02343536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Study NCT02343536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Study NCT02343536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT02343536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Study NCT02217319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min). After induction of anesthesia the propofol infusion is stopped and patients receive 1 MAC Sevoflurane over 30 min. Then the propofol infusion is restarted and Sevoflurane is washed out.
Study NCT02217319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TIVA
Description: Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min).
Study NCT01286766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DCS (docetaxel with cisplatin with TS-1)
Description: 1. S-1: 70 mg/m2 #2 bid PO, D1-14~2. Docetaxel 30 mg/m2 IVF (for 1 hr) D1 and D8~3. Cisplatin 30 mg/m2 IVF (for 2 hrs, without hydration) D1 and D8, repeated by 3 weeks.
Study NCT01286766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DCF (docetaxel with cisplatin with 5-FU)
Description: 1. 5-FU: 1,000 mg/m2 CI, D1-3~2. Docetaxel 60 mg/m2 IVF (for 1 hr) D1 followed by~3. Cisplatin 60 mg/m2 IVF (for 2 hrs, with hydration) D1, repeated by 3 weeks.~   * Intercycle or intracycle dose modification is indicated if ≥G3 hematologic toxicity (except anemia) or ≥G3 non-hematologic toxicity (except alopecia)~  * treatment is repeated until 4 cycles
Study NCT03775369 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: endurance training
Description: physical activity and exercising (PAE)
Study NCT03775369 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: social support and counseling
Description: social support and counseling
Study NCT03775369 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: resistance training
Description: physical activity and exercising (PAE)
Study NCT03910517 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT01180153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 oxaliplatin
Description: S-1 (20mg, 25mg); L-OHP (50 mg)
Study NCT02041104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bread with added beta-glucans
Description: Participants will daily consume bread with high content of beta-glucans. They will approximately consume 6 g beta-glucans per day in 200 g of bread. Intervention period will be 4 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics
Study NCT02041104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Bread without added beta-glucans
Description: Participants will daily consume placebo bread without any added beta-glucans (approximately 200 g per day). Intervention period will be 4 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics.
Study NCT04360395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gait Therapy
Description: The therapeutic gait training protocol will consist of 24-treatment sessions that will be performed 3 times-a-week for an 8-week period. All therapeutic exercises will be performed under the direction of a licensed pediatric physical therapist. Any sessions missed will be added on to the 8-week period. Each intervention session will consist of over-ground gait activities that will be completed in a 60 minute session with rests as needed. The key ingredients of the therapy will include: 1) activities of adequate intensity that promote gait adaptation and gait speed sustainment, 2) exploratory activities that enhance the somatosensory experience through rich/novel movement, and 3) optimally challenging activities that emphasize planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints.
Study NCT01338714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compound Herbal Formula (RHD-1)
Description: 100 ml/per day
Study NCT01338714 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: dilute RHD-1
Description: 100 ml/per day
Study NCT01972035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Experimental Arm
Study NCT01972035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: Standard of care
Study NCT01739413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anesthesia
Description: Patients will be randomized to receive either epidural or general anesthesia for pain management throughout their surgery.
Study NCT01739413 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia
Description: Patients will be randomized to receive either epidural or general anesthesia for pain management throughout their surgery.
Study NCT03345758 — intervention group
Intervention type: OTHER
Intervention: outcome
Description: telephone to patients to finish SF-36 (the MOS item short from health survey,SF-36)，EQ-5D(EuroQol-5 Dimensions,EQ-5D)， AMT-4（Abbreviated Mental Test-4,AMT-4）and MMSE（Mini-mental State Examination,MMSE） to make assessments of their physical and mental health, cognitive function and social adaptation after discharge
Study NCT02520791 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-ICOS Monoclonal Antibody MEDI-570
Description: Given IV
Study NCT02520791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02520791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT04533139 — intervention group
Intervention type: DRUG
Intervention: Influenza vaccine
Description: influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season antigens: A/New Caledonia/20/99(H1N1)-like, A/Wyoming/3/2003(H3N2), and B/Shanghai/361/2002-like antigens~2005-2006 season antigens: A/New Caledonia/ 20/00(H1N1)-like, A/California/7/2004 (H3N2)-like, and B/Shanghai/361/2002-like antigens
Study NCT03958513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 1.5 ml 0.25% bupivacaine for 1 inch incision will be given before closure of ports in patients undergoing laparoscopic cholecystectomy
Study NCT03958513 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: 1.5 ml 0.9% NACl for 1 inch incision will be given before closure of ports in patients undergoing laparoscopic cholecystectomy
Study NCT03349736 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pelvic Floor Muscle Training
Description: All the women will receive information and instruction/guidance exercise individually and in groups on PFMT on the first day of their visit. Following this, the women are advised to perform daily PFMT at home which includes 10 sec hold X 10 times X 3 sets. Women will record their home PFMT using an exercise diary. During the follow-up, women will attend the PFMT in a group or individual led by a Physiotherapists (to motivate and to ensure women are performing the PFMT correctly). Exercise diary will be collected in every follow up so that the information is retained even if the women discontinued or deviate from intervention protocols.
Study NCT01646775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epidural fentanyl
Description: withold epidural fentanyl
Study NCT01646775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural fentanyl
Description: withold epidural fentanyl